NCT06443866View on ClinicalTrials.gov

I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

January 31, 2029

Study Completion Date

December 31, 2029

Conditions
Thyroid CancerRAI-Refractory Thyroid Cancer
Interventions
DIAGNOSTIC_TEST

Disease status detection

RAI dose determination

DIAGNOSTIC_TEST

Theranostic dosimetry

Theranostic dosimetric evaluation for optimization of RAI therapy of thyroid cancer

DRUG

I-124 PET/CT imaging

Theranostic dosimetry for optimization of RAI therapy for Thyroid Cancer

Trial Locations (1)

33181

RECRUITING

Miami Cancer Research Center, North Miami

All Listed Sponsors
lead

Miami Cancer Research Center, Inc.

OTHER